A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment

PharmacoEconomics

Volumn 20, Issue SUPPL. 1, 2002, Pages 21-30

  Veenstra, D L ^a   Ramsey, S D ^a,b   Sullivan, S D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG FORMULARY; DRUG SELECTIVITY; DRUG UTILIZATION; MANAGED CARE; MANAGED CARE ORGANIZATION; MATHEMATICAL MODEL; PATIENT CARE; PEER REVIEW; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; VALIDATION PROCESS;

EID: 0036258090     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220001-00003     Document Type: Article

References (28)

1. Exploding type II
2. Economic consequences of diabetes mellitus in the US, in 1997
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Update
5. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
6. Effect of improved glycemic control on health care costs and utilization
7. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations
8. Developing guidance for budget impact analysis
9. Assessing quality in decision analytic cost-effectiveness models
10. The global diabetes model: User friendly version 3.0
11. Outline of a diabetes disease management model: Principles and applications
12. The Mt. Hood challenge: Cross-testing two diabetes simulation models
13. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)
14. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
15. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM
16. Efficacy of metformin in the treatment of NIDDM. Meta-analysis
17. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
18. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
19. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients
20. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials
21. Average cost per patient for 30 days treatment with lowest usual daily dose, based on data provided by Scott Levin's source™ prescription audit (SPA): March 2000 to February 2001
22. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)